Korea Improves New Drug Pricing Incentives After Industry Calls
This article was originally published in PharmAsia News
Executive Summary
South Korea’s government is moving to improve reimbursement prices for new drugs developed by domestic companies amid repeated calls from the pharma industry, as part of a series of measures to increase R&D incentives for novel drugs that will be approved locally for the first time in the world.